Citing a lack of consumer acceptance, Pfizer, Inc., has announced that it will no longer market Exubera, its inhaled insulin product. In the announcement, the company said the product has been safe and effective, but too few patients and practitioners are using it to warrant further investment. Patients using Exubera are advised to work with their practitioners to make the transition to other insulin products. For more information, visit http://www.exubera.com.